Multinational drug manufacturers’ revenues up, profit down

28 foreign-invested firms, except for Pfizer Korea, Janssen Korea and Boehringer Ingelheim Korea, saw their revenues jump last year, but their ability to generate cash from a variety of operating activities fell on worsening profitability.

In its audit report, the Financial Supervisory Service said that GlaxoSmithKline (GSK) ranked first in terms of annual sales showing 434.2 billion won las...